CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins.[5] It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases.[6]
CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice.[7]
As a drug target
An immunotoxin, BL22, that targets this receptor is being tested at the NIH.[8]
As a treatment for acute lymphoblastic leukemia (ALL), Inotuzumab ozogamicin is an antibody-drug conjugate that targets this molecule.
Interactions
CD22 has been shown to interact with Grb2,[9][10] PTPN6,[10][11][12][13][14] LYN,[9][12] SHC1[9] and INPP5D.[9]
| This article uses material from the Wikipedia article Metasyntactic variable, which is released under the Creative Commons Attribution-ShareAlike 3.0 Unported License. |